Patrick Johnson, President of Sydnexis discusses numerous topics including the formulation and stability of Sydnexis' proprietary investigational drug for pediatric myopia progression.
By using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
